12月11日 - ** 制药商Biohaven BHVN.N股价上涨8.5%至11.50美元
** 该公司称，其试验性疗法BHV-1510与Regeneron Pharmaceuticals公司
** 公司 称，每三周接受一次治疗的患者有 72.7% 的确诊反应
** 正在晚期癌症患者 中 测试这种联合疗法 -BHVN
** 加拿大皇家银行资本市场（RBC Capital Markets）称，"这些疗效和安全性结果令人鼓舞"。
** 包括盘中走势在内，该股今年累计下跌 69.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.